To ask the Secretary of State for Health what funding the Government will make available to the Pharmacy Regulation and Leadership Oversight Group in each of the next three financial years.

To ask the Secretary of State for Health what funding the Government will make available to the Pharmacy Regulation and Leadership Oversight Group in each of the next three financial years.

To ask the Secretary of State for Health how many people were (a) admitted to and (b) discharged from hospital with a primary or secondary diagnosis of (i) malnutrition, (ii) nutritional anaemias and (iii) other nutritional deficiencies in each year from 1997-98 to 2006-07; and if he will provide a...

To ask the Secretary of State for Health how many people were (a) admitted to and (b) discharged from hospital with a primary or secondary diagnosis of (i) malnutrition, (ii) nutritional anaemias and (iii) other nutritional deficiencies in each year from 1997-98 to 2006-07; and if he will provide a...

To ask the Secretary of State for Health when he intends to publish his Department's strategy for tackling obesity; which (a) Government Departments, (b) Government agencies, (c) other organisations and (d) other interested parties are involved in its development; and if he will make a statement.

To ask the Secretary of State for Health when he intends to publish his Department's strategy for tackling obesity; which (a) Government Departments, (b) Government agencies, (c) other organisations and (d) other interested parties are involved in its development; and if he will make a statement.

To ask the Secretary of State for Health what steps he has taken to increase public awareness of the body mass index as an indicator of health; and if he will make a statement.

To ask the Secretary of State for Health what steps he has taken to increase public awareness of the body mass index as an indicator of health; and if he will make a statement.

To ask the Secretary of State for Health what estimate he has made of the proportion of parents who will access the online height-weight calculator being developed by his Department.

To ask the Secretary of State for Health what estimate he has made of the proportion of parents who will access the online height-weight calculator being developed by his Department.

To ask the Secretary of State for Health what recent discussions (a) he, (b) Ministers in his Department and (c) officials have had with (i) hon. Members and (ii) Members of the House of Lords on (A) embryonic stem cell research and (B) the Human Fertilisation and Embryology Bill; and...

To ask the Secretary of State for Health what recent discussions (a) he, (b) Ministers in his Department and (c) officials have had with (i) hon. Members and (ii) Members of the House of Lords on (A) embryonic stem cell research and (B) the Human Fertilisation and Embryology Bill; and...

To ask the Secretary of State for Health how many patients were prescribed (a) methadone and (b) other hard drug substitutes in the latest period for which figures are available; and what the size is of the waiting list for substitutes programmes.

To ask the Secretary of State for Health how many patients were prescribed (a) methadone and (b) other hard drug substitutes in the latest period for which figures are available; and what the size is of the waiting list for substitutes programmes.

To ask the Secretary of State for Health what the average waiting time was to move from the waiting list to treatment programmes for hard drug substitutes in the latest period for which figures are available.

To ask the Secretary of State for Health what the average waiting time was to move from the waiting list to treatment programmes for hard drug substitutes in the latest period for which figures are available.

To ask the Secretary of State for Health what steps he is taking to reduce health inequalities in England.

To ask the Secretary of State for Health what steps he is taking to reduce health inequalities in England.

To ask the Secretary of State for Health for what reasons (a) Blackburn with Darwen Primary Care Trust, (b) East Lancashire Primary Care Trust and (c) Milton Keynes Primary Care Trust did not submit COVER reports in the second quarter of 2007; and when each primary care trust (i) last...

To ask the Secretary of State for Health for what reasons (a) Blackburn with Darwen Primary Care Trust, (b) East Lancashire Primary Care Trust and (c) Milton Keynes Primary Care Trust did not submit COVER reports in the second quarter of 2007; and when each primary care trust (i) last...

(3) if he will hold discussions with (a) the Medicines and Healthcare Products Regulatory Agency and (b) the European Medicines Agency to ensure that manufacturers of biosimilar medicines submit full clinical trial data on each indication for their products rather than extrapolated data from the reference product;

(3) if he will hold discussions with (a) the Medicines and Healthcare Products Regulatory Agency and (b) the European Medicines Agency to ensure that manufacturers of biosimilar medicines submit full clinical trial data on each indication for their products rather than extrapolated data from the reference product;

(2) if the Government will take steps to preclude the automatic substitution of brands with similar biological medicines to ensure patients are not put at unnecessary risk from potential adverse drug reactions;

(2) if the Government will take steps to preclude the automatic substitution of brands with similar biological medicines to ensure patients are not put at unnecessary risk from potential adverse drug reactions;

(4) if he will ensure that biosimilar medicine packaging and accompanying patient information leaflets (a) contain details of the formulation and manufacturing process for the biosimilar agent and (b) make reference to the potential risk of not being able to determine which drug resulted in an adverse drug reaction as...

(4) if he will ensure that biosimilar medicine packaging and accompanying patient information leaflets (a) contain details of the formulation and manufacturing process for the biosimilar agent and (b) make reference to the potential risk of not being able to determine which drug resulted in an adverse drug reaction as...

To ask the Secretary of State for Health (1) how many biosimilar medicines are licensed for use in the United Kingdom;

To ask the Secretary of State for Health (1) how many biosimilar medicines are licensed for use in the United Kingdom;

To ask the Secretary of State for Health what the (a) pre-market launch and (b) post-market launch medicines are on which the National Prescribing Centre provides evaluated information; and which condition each treats.

To ask the Secretary of State for Health what the (a) pre-market launch and (b) post-market launch medicines are on which the National Prescribing Centre provides evaluated information; and which condition each treats.

To ask the Secretary of State for Health what (a) estimate he has made of and (b) research he has (i) commissioned and (ii) evaluated on the number of patients who have had adverse reactions to medicines due to (A) prescription and (B) use after the use-by date; and if...

To ask the Secretary of State for Health what (a) estimate he has made of and (b) research he has (i) commissioned and (ii) evaluated on the number of patients who have had adverse reactions to medicines due to (A) prescription and (B) use after the use-by date; and if...

To ask the Secretary of State for Health what guidance he has issued on the prescribing of Lucentis; and if he will make a statement.

To ask the Secretary of State for Health what guidance he has issued on the prescribing of Lucentis; and if he will make a statement.

(4) what the total cost to the public purse is of the Catch it, Bin it, Kill it campaign, announced by his Department on 28 November; and if he will make a statement.

(4) what the total cost to the public purse is of the Catch it, Bin it, Kill it campaign, announced by his Department on 28 November; and if he will make a statement.